Q-omics provides the consensus-scored TBR1 profile across patient tissues and cancer cell-line models. TBR1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TBR1 is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, TBR1 protein abundance shows 22,364 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, LUAD, and GBM as cancer lineages where TBR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBR1 survival associations across molecular data types. TBR1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (11) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBR1 RNA expression–survival associations across cancer types. High TBR1 expression shows unfavorable associations in ACC, LIHC, KIRP, BLCA, UVM and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TBR1 RNA expression.
This table summarizes TBR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 4. The strongest signals are observed in BRCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TBR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBR1 shows lower tumor expression in THCA, KICH and KIRC and higher tumor expression in LUAD, BRCA and LUSC. The LUAD box plot shows higher TBR1 RNA expression in tumor versus normal tissue (log2 FC = +0.065, t-test p = .007).
This table shows molecular features associated with TBR1 in patient tissues and cancer cell lines. In patient samples, TBR1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TBR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
